Failure of somatostatin to affect human chorionic somatomammotropin and human chorionic gonadotropin secretion in vitro.
The effect of somatostatin (SRIF) on human chorionic somatomammotropin (hCS) secretion was studied in human placental explants cultured in vitro. In the experimental flasks, SRIF was added in a concentration of 10, 100, and 1000 ng/ml media; hCS levels measured by RIA were not different from those found in the control flasks. In separate experiments, we investigated the action of SRIF on hCG secretion by a human malignant choriocarcinoma cell line maintained in tissue culture. SRIF (1000 ng/ml) did not inhibit basal or dibutyryl cAMP-induced stimulation of hCG secretion. These results suggest that somatostatin does not suppress hCS or hCG release in vitro from normal or malignant trophoblast, respectively.
D003994:Bucladesine / Q000494:pharmacology; D002460:Cell Line; D002822:Choriocarcinoma / Q000378:metabolism; D006063:Chorionic Gonadotropin / Q000378:metabolism*; D005260:Female; D006801:Humans; D009924:Organ Culture Techniques; D010920:Placenta / Q000187:drug effects / Q000378:metabolism*; D010928:Placental Lactogen / Q000378:metabolism*; D011247:Pregnancy; D013004:Somatostatin / Q000494:pharmacology*; D014594:Uterine Neoplasms / Q000378:metabolism
D006063:Chorionic Gonadotropin; D013004:Somatostatin; D003994:Bucladesine; D010928:Placental Lactogen